Nagelfar
Bluelight Crew
- Joined
- Nov 23, 2007
- Messages
- 2,527
Why aren't simple medications for agonism/antagonism of the *highly variable* sub-type receptor classes (with regard to their affectations) in the monoamine system, biogenic amines, etc. singled out for just agonism or antagonism of one DA, 5-HT or NE receptor sub-type with no other appreciable affinity, and included together in one formulation with other chemicals which are exactly as selective, but for another site and agonism for some and antagonism for others? Wouldn't this be the most logical direct and intelligent/rational (and educational to academia + research of behavioral relationship to what brain function!) direction for anti-depressant "SSRI" type of drugs. Instead of 200mg of one compound that has fairly random affinity for a few different spots where the subjective good results are yielded in the over-all observation of how it suits depression?
Wouldn't putting, say, seven compounds at ultra low dose (the highest of which should start @ "NOEL = No Observed Effect Level, the highest dose known to show no effect"), for their subtle synergy in the bigger picture each with its own unique level of affinity to just one site, where it selectively activates it or blocks it from activation (specifically in the serotonin receptor sub-types where some are related to dysphoria and others with mood elevation)
Shouldn't this, or wouldn't this be the logical end point of rational drug design when it comes to straight-forward and pure desire for patient's welfare?
Wouldn't putting, say, seven compounds at ultra low dose (the highest of which should start @ "NOEL = No Observed Effect Level, the highest dose known to show no effect"), for their subtle synergy in the bigger picture each with its own unique level of affinity to just one site, where it selectively activates it or blocks it from activation (specifically in the serotonin receptor sub-types where some are related to dysphoria and others with mood elevation)
Shouldn't this, or wouldn't this be the logical end point of rational drug design when it comes to straight-forward and pure desire for patient's welfare?